Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 335-341 , June 2010

Possibilities of new therapeutic strategies in brain tumors

References 

  1. Magnani C, Aareleid T, Viscomi S, Pastore G, Berrino F. Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992: the EUROCARE study. Eur J Cancer. 2001;37(6):711–721
  2. Campbell JW, Pollack IF. Cerebellar astrocytomas in children. J Neurooncol. 1996;28(2–3):223–231
  3. Benesch M, Eder HG, Sovinz P, Raith J, Lackner H, Moser A, et al. Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr Neurosurg. 2006;42(3):159–164
  4. Qaddoumi I, Sultan I, Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: why and how?. Cancer Biol Ther. 2009;8:(1)
  5. Muller HL, Albanese A, Calaminus G, Hargrave D, Garre ML, Gebhardt U, et al. Consensus and perspectives on treatment strategies in childhood craniopharyngioma: results of a meeting of the Craniopharyngioma Study Group (SIOP), Genova, 2004. J Pediatr Endocrinol Metab. 2006;19(Suppl. 1):453–454
  6. Fisher PG, Jenab J, Gopldthwaite PT, Tihan T, Wharam MD, Foer DR, et al. Outcomes and failure patterns in childhood craniopharyngiomas. Childs Nerv Syst. 1998;14(10):558–563
  7. Palma L, Celli P, Mariottini A. Long-term follow-up of childhood cerebellar astrocytomas after incomplete resection with particular reference to arrested growth or spontaneous tumour regression. Acta Neurochir (Wien). 2004;146(6):581–588[discussion 588]
  8. Bouffet E, Baranzelli MC, Patte C, Portas M, Edan C, Chastagner P, et al. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d’Oncologie Pediatrique. Br J Cancer. 1999;79(7–8):1199–1204
  9. Finlay J, da Silva NS, Lavey R, Bouffet E, Kellie SJ, Shaw E, et al. The management of patients with primary central nervous system (CNS) germinoma: current controversies requiring resolution. Pediatr Blood Cancer. 2008;51(2):313–316
  10. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813–820
  11. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202–4208
  12. Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol. 2005;75(3):287–299
  13. Merchant TE, Mulhern RK, Krasin MJ, Kun LE, Williams T, Li C, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol. 2004;22(15):3156–3162
  14. Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest. 2006;24(1):77–81
  15. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–248
  16. MacDonald TJ. Aggressive infantile embryonal tumors. J Child Neurol. 2008;23(10):1195–1204
  17. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978–986
  18. Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH, Bostrom BC, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group. J Clin Oncol. 1998;16(1):222–228
  19. Mason WP, Goldman S, Yates AJ, Boyett J, Li H, Finlay JL. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma – a report of the Children’s Cancer Group. J Neurooncol. 1998;37(2):135–143
  20. Finlay JL, Dhall G, Boyett JM, Dunkel IJ, Gardner SL, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(6):806–811
  21. Gururangan S, Dunkel IJ, Goldman S, Garvin JH, Rosenblum M, Boyett JM, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol. 1998;16(7):2486–2493
  22. Kalifa C, Hartmann O, Demeocq F, Vassal G, Couanet D, Terrier-Lacombe MJ, et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant. 1992;9(4):227–233
  23. Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, et al. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys. 2008;
  24. Gajjar A. High-dose chemotherapy for recurrent medulloblastoma: time for a reappraisal. Cancer. 2008;112(8):1643–1645
  25. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. 1995;37(4):655–666[discussion 666–7]
  26. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832–845
  27. Berger C, Thiesse P, Lellouch-Tubiana A, Kalifa C, Pierre-Kahn A, Bouffet E. Choroid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery. 1998;42(3):470–475
  28. Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004;22(14):2877–2884
  29. Finlay JL, Wisoff JH. The impact of extent of resection in the management of malignant gliomas of childhood. Childs Nerv Syst. 1999;15(11–12):786–788
  30. Albright AL, Wisoff JH, Zeltzer P, Boyett J, Rorke LB, Stanley P, et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children’s Cancer Group. Pediatr Neurosurg. 1995;22(1):1–7
  31. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007;107(Suppl. 1):1–4
  32. Song DK, Lonser RR. Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol. 2008;23(10):1231–1237
  33. Groothuis DR, Benalcazar H, Allen CV, Wise RM, Dills C, Dobrescu C, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res. 2000;856(1–2):281–290
  34. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2007;25(29):4622–4627
  35. Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. 2002;4(2):102–108
  36. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer. 2007;110(7):1542–1550
  37. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996
  38. Cohen K, Heideman R, Zhou T, Holmes E, Burger P, Brat D, et al. Should temozolomide be the standard of care for children with newly diagnosed high -grade gliomas? Results of the Children’s Oncology Group ACNS0126 Study. Neuro-oncology. 2007;9(2):188
  39. Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res. 2008;14(2):523–532
  40. Moghrabi A, Hershon L, Rousseau P, Decarie JC, Friedman HS, Zhou T, et al. A phase I/II feasibility study of oral etoposide given concurrently with radiotherapy followed with dose-intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma COG P9631. In: 13th international symposium on pediatric neuro-oncology 2008 JUN 29–JUL 02, 2008; Chicago, IL: Neuro-oncology; 2008. p. 476.
  41. Jakacki RI, Burger PC, Zhou T, Holmes E, Packer R, Goldwein J, et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. In: 2007 ASCO annual meeting 2007; 2007. p. 2017.
  42. ACNS0332. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=511991&version=patient&protocolsearchid=5798903.
  43. Stempak D, Gammon J, Stephens D, Feltis A, Bartels U, Fryer C, et al. A Canadian multicenter pilot study of extended low-dose temozolomide and radiation therapy in pediatric brainstem glioma. In: 13th international symposium on pediatric neuro-oncology; 2008; Chicago, IL: Neuro-oncology; 2008. p. 391.
  44. Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, et al. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol. 2004;22(10):1934–1943
  45. Bouffet E, Doz F, Demaille MC, Tron P, Roche H, Plantaz D, et al. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?. Br J Cancer. 1998;77(8):1321–1326
  46. Chi SN, Gardner SL, Levy AS, Knopp EA, Miller DC, Wisoff JH, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004;22(24):4881–4887
  47. Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, et al. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol. 2005;71(2):181–187
  48. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045–1047
  49. Broxterman HJ, Lankelma J, Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist Updat. 2003;6(3):111–127
  50. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006;42(14):2335–2342
  51. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006;28(11):720–728
  52. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14(6):1922–1927
  53. Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103(12):2636–2642
  54. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27(11):573–581
  55. Slavc I, Schuller E, Falger J, Gunes M, Pillwein K, Czech T, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol. 2003;64(3):239–247
  56. Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowtiz M, et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005;23(3):525–531
  57. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003;21(1):143–147
  58. Habrand JL, De Crevoisier R. Radiation therapy in the management of childhood brain tumors. Childs Nerv Syst. 2001;17(3):121–133
  59. Penagaricano JA, Papanikolaou N, Yan Y, Ratanatharathorn V. Application of intensity-modulated radiation therapy for pediatric malignancies. Med Dosim. 2004;29(4):247–253
  60. Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol. 2004;1(2):97–103[quiz 1 p following 111]
  61. MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys. 2008;71(4):979–986
  62. Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer. 2008;51(1):110–117
  63. Zacharatou Jarlskog C, Paganetti H. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. Int J Radiat Oncol Biol Phys. 2008;72(1):228–235
  64. Hodgson DC, Goumnerova LC, Loeffler JS, Dutton S, Black PM, Alexander E, et al. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys. 2001;50(4):929–935
  65. Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys. 2008;71(1):87–97
  66. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–160
  67. Geyer JR, Boyett J, Douglas J, Phillips P, Young-Poussaint T, Packer R, et al. Phase I Trial of ZD1839 (IressaTM) and radiation in pediatric patients newly diagnosed with brain stem tumors or incompletely resected supratentorial malignant gliomas. In: ASTRO 46th annual meeting, 2004. Atlanta: International Journal of Radiation Oncology Biology Physics; 2004. p. S251.
  68. Fouladi M, Laningham F, Wu J, O’Shaughnessy MA, Molina K, Broniscer A, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol. 2007;25(30):4806–4812
  69. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007;25(21):3137–3143
  70. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009;52(2):169–176
  71. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26(6):919–924
  72. Gururangan S, Turner CD, Stewart CF, O’Shaughnessy M, Kocak M, Poussaint TY, et al. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008;14(4):1124–1130
  73. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2005;23(25):6172–6180
  74. Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s Oncology Group study. Cancer. 2007;110(11):2535–2541
  75. Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008;10(3):341–347
  76. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490–498
  77. Kun LE, Gajjar A, Muhlbauer M, Heideman RL, Sanford R, Brenner M, et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa. 7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995;6(9):1231–1255
  78. Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg. 2000;92(2):249–254

PII: S0305-7372(10)00029-0

doi: 10.1016/j.ctrv.2010.02.009

Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 335-341 , June 2010

Article Tools